Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Cancer ; (12): 805-814, 2011.
Article Dans Anglais | WPRIM | ID: wpr-294456

Résumé

In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.


Sujets)
Animaux , Femelle , Humains , Antinéoplasiques , Pharmacologie , Apoptose , Prolifération cellulaire , Résistance aux médicaments antinéoplasiques , Récidive tumorale locale , Thérapie virale de cancers , Méthodes , Tumeurs de l'ovaire , Anatomopathologie , Thérapeutique , Virologie , Virus de la stomatite vésiculeuse de type Indiana , Physiologie , Réplication virale
SÉLECTION CITATIONS
Détails de la recherche